Close Menu

NEW YORK (360Dx) – Oncimmune Holdings said today that it has obtained the CE mark for its autoantibody, blood-based EarlyCDT-Lung test in an ELISA kit format.

The test can detect lung cancer up to four years earlier than other methods, the firm said, adding that it will now be made available "to hospitals around the world for running in their own laboratories."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.